Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
NASA shares first photos of Earth taken by Artemis II - 2Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
- 3Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- 4Banks for High Fixed Store Rates: Amplify Your Reserve funds
- 5Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- 'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off
- The most exciting exoplanet discoveries of 2025
- Picking the Right Home Machines: A Commonsense Aide
- Two separate Israeli espionage cases uncover Iran-linked activities in Jerusalem, Ashkelon
- James Webb Space Telescope's mysterious 'little red dots' may be black holes in disguise
- Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- The best ice packs for coolers of 2026, tested and reviewed
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Who was Haytham Ali Tabatabai, Hezbollah's military leader killed by Israel?
